Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II master protocol of AZD2936 or MEDI5752 plus chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma
2022-002840-29Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Jan 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of rilvegostomig and volrustomig in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by AstraZeneca. Primary endpoints: Objective response rate and PFS6. Started Jan 2023; status: active.
02
Drugs
rilvegostomigvolrustomig
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2022-002840-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002840-29.